OMEICOS
Key Facts
Invested since | 2013 |
Based in | Berlin |
About the company
OMEICOS Therapeutics develops a novel, first-in-class, small molecule drug addressing a new Mode of Action for the treatment and prevention of atrial fibrillation.
Do you want to
know more about this company?
OMEICOS in the news
